Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients 40 years of age and older - diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy - dFLC greater than 23 mg/L - abnormal FLC ratio - If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion. Who Should NOT Join This Trial: - Patients younger than 40 years of age are not eligible - Patients with a previous finding of amyloid in other biopsies will not be included - Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients 40 years of age and older * diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy * dFLC greater than 23 mg/L * abnormal FLC ratio * If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion. Exclusion Criteria: * Patients younger than 40 years of age are not eligible * Patients with a previous finding of amyloid in other biopsies will not be included * Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible

Locations (13)

University of Alabama Hospital
Birmingham, Alabama, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
Cleveland Clinic Florida, Weston Hospital
Weston, Florida, United States
Tufts Medical Center
Boston, Massachusetts, United States
Columbia University Irving Medical Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States
UNC Lineberger Comprehensive Cancer Center
Durham, North Carolina, United States
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
UT Southwestern, Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States
University of Utah, Huntsman Cancer Hospital
Salt Lake City, Utah, United States
VCU Medical Center
Richmond, Virginia, United States